Bhargavi Patham is an Endocrinology/Metabolic physician affiliated with Houston Methodist. OpenAlex indexes 25 publications with 537 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6550 Fannin St
Houston, TX 770302717
Telephone
713-441-6722Provider last certified this registry record 12 Apr 2023.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascensia Diabetes Care Us Inc.Program year20251 payment
- Abbott LaboratoriesProgram year20251 payment
- Abbott LaboratoriesProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
71.5%Insulin Analog31.8%Lantus Solostar19%Novolog Flexpen15%Tresiba Flextouch U-10010%Toujeo Max Solostar10%Tresiba Flextouch U-20010%Humalog Kwikpen U-1008%Fiasp Flextouch8%Toujeo Solostar7%Basaglar Kwikpen U-1006%Insulin Lispro Kwikpen U-1006%Insulin Lispro3%Part D<11 patientsGLP-1 receptor agonist11.9%Mounjaro36%Ozempic33%Trulicity31%Part D<11 patients+ 5 more classes in this area
Cardiovascular
15.9%Statin12.4%Atorvastatin Calcium48%Rosuvastatin Calcium42%Pravastatin Sodium10%Part D<11 patientsCholesterol absorption inhibitor3.5%Ezetimibe100%Part D≥14 patientsHormonal (systemic)
12.6%l-Thyroxine11.4%Levothyroxine Sodium85%Synthroid15%Part D<11 patientsCalcium-sensing Receptor Agonist1.2%Cinacalcet Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Therapeutic Plasma Exchange in Severe Thyrotoxicosis: Clinical Observations From a Case Series
The Journal of Clinical Endocrinology & Metabolism
2026 - A Unified System-Wide Electronic Dashboard for Inpatient Glucose Management Across a Large Health System
Journal of Diabetes Science and Technology
2026 - Medical Management of Obesity: Current Trends and Future Perspectives
Methodist DeBakey Cardiovascular Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bita Esmaeli, MD
Houston Methodist
Sherif Nagueh, MD
Houston Methodist
Neal Kleiman, MD
Houston Methodist
Miguel Quinones, MD
Houston Methodist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”